Testing effectiveness (Phase 2)Study completedNCT02145403
What this trial is testing
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Who this might be right for
Hematologic MalignanciesRelapseGraft-Versus-Host Disease
University of Michigan Rogel Cancer Center 53